37P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in genetically selected microsatellite stable colorectal cancer patients
Natalie Cook(The Christie NHS Foundation Trust), Van K. Morris(The University of Texas MD Anderson Cancer Center), Simon A. Woodcock(Bio-Medical Science (South Korea)), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Bert H. O’Neil(Indiana University Health), R.H. Wilson(Beatson West of Scotland Cancer Centre), Ian Chau(Royal Marsden NHS Foundation Trust), David M. Wilson(AstraZeneca (Singapore)), Joan Maurel(Breast Cancer Research Foundation), Mark Saunders(Manchester Academic Health Science Centre), R. Garcia-Carbonero(Hospital Universitario 12 De Octubre), J. Graham(NHS Greater Glasgow and Clyde), S-H. Beom(Yonsei University), Elspeth Asken(Redx Pharma (United Kingdom)), Hilary H. Timmis(Redx Pharma (United Kingdom)), T.W. Kim(Ulsan College), Jane Robertson(Cancer Research UK), Shamim Saleha(Genesis Medical Center), J.A. Bridgewater(CRUK Lung Cancer Centre of Excellence), Louise Goodwin(Redx Pharma (United Kingdom))
Cited by 5
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k